세계의 노인용 의약품 시장 보고서(2025년)

Geriatric Medicines Global Market Report 2025

US $ 4,490 ￦ 6,242,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,023,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,803,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

노인용 의약품 시장 규모는 향후 몇 년 동안 빠르게 성장할 것으로 예상되며, 2029년까지 연평균 16.2%의 성장률로 2조 6,048억 6,000만 달러에 달할 것으로 예측됩니다. 예측 기간 동안 예상되는 성장은 노화와 관련된 건강 상태의 유병률 증가, 노인 인구 증가, 의료비 증가, 노인 의료 확대, 고혈압 유병률 증가 등의 요인에 기인합니다. 이 기간 동안 예상되는 주요 동향으로는 디지털 알약 및 웨어러블 건강 기기의 사용, 여러 약물을 안전하게 관리할 수 있는 도구 및 전략의 개발, 줄기세포 및 유전자 치료의 발전, 원격 의료 플랫폼의 활용 확대, 노화 관련 질환의 조기 진단 및 예방의 혁신 등이 있습니다.

노인용 의약품 시장의 성장은 노화와 관련된 건강 상태의 유병률 증가에 의해 주도될 것으로 예측됩니다. 이러한 질병은 나이가 들어감에 따라 더 흔해지거나 더 심각해지는데, 이는 주로 자연적인 노화 과정에 기인합니다. 평균 수명 증가, 의료 기술의 발전, 노인 인구 증가 등의 요인이 이러한 건강 문제의 발생을 증가시키고 있습니다. 노인의약품은 이러한 노화 관련 증상을 관리하는 데 있어 매우 중요하며, 노인의 삶의 질과 건강관리 성과를 향상시키는 전문적 치료를 제공합니다. 예를 들어, OHID(Office for Health Improvement and Disparities)가 2023년 3월 발표한 보고서에 따르면, 영국에서는 2022년 16세 이상 인구의 17.6%가 관절염, 만성관절장애 등 장기적인 근골격계(MSK) 질환을 앓고 있는 것으로 보고되고 있습니다. 보고되고 있습니다. 이는 2021년 17.0%에서 증가한 수치입니다. 결과적으로, 노화와 관련된 건강 상태의 유병률 증가는 노인용 의약품 시장의 성장을 가속하고 있습니다.

노인용 의약품 시장의 주요 기업들은 고령화 사회의 효과적인 치료법에 대한 수요 증가에 대응하기 위해 혁신적인 당뇨병 치료제 개발에 주력하고 있습니다. 당뇨병 치료에는 안전성, 유효성, 환자 결과 측면에서 기존 치료법을 능가하는 것을 목표로 관리를 개선하고 치료 가능성을 제공하는 최첨단 치료법이 포함됩니다. 예를 들어, 2023년 8월 인도 제약사 Akums Drugs &&Pharmaceuticals Ltd.는 빌다글립틴 SR과 메트포르민 SR의 새로운 병용요법을 발표했습니다. 이 새로운 제제는 고령자의 2형 당뇨병 관리에 특화되어 혈당 조절을 개선하는 동시에 저혈당 및 체중 증가와 같은 고령자에게 특히 중요한 문제를 해결해줍니다. 이 약은 인슐린 분비를 촉진하고 혈당 수치를 낮춤으로써 안전성과 유효성을 모두 충족시킵니다. 이 약은 인도 식약청(DCGI)의 승인을 받았습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 노인용 의약품 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 노인용 의약품 시장 : 성장률 분석
• 세계의 노인용 의약품 시장 실적 : 규모와 성장, 2019-2024
• 세계의 노인용 의약품 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 노인용 의약품 전체 시장(TAM)

제6장 시장 세분화

• 세계의 노인용 의약품 시장 : 치료제별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 진통제
• 강압제
• 스타틴
• 양성자 펌프 억제제
• 항응고제
• 항정신병제
• 기타 치료제
• 세계의 노인용 의약품 시장 : 상태별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 심혈관계
• 관절염
• 신경질환
• 암
• 골다공증
• 호흡기
• 기타 조건
• 세계의 노인용 의약품 시장 : 투여 경로별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 경구
• 비경구
• 기타 투여 경로
• 세계의 노인용 의약품 시장 : 유통 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 병원 약국
• 소매 약국
• 온라인 약국
• 세계의 노인용 의약품 시장 : 진통제별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 비오피오이드 진통제(Acetaminophen, NSAIDs)
• 오피오이드 진통제(Morphine, Oxycodone)
• 국소 진통제(Lidocaine Patches)
• 세계의 노인용 의약품 시장 강압제별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 안지오텐신 전환 효소(ACE) 억제제
• 안지오텐신 II 수용체 길항제(ARB)
• 베타 차단제
• 칼슘 채널 차단제
• 이뇨제
• 알파 차단제
• 세계의 노인용 의약품 시장 : 스타틴별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Atorvastatin
• Simvastatin
• Rosuvastatin
• Pravastatin
• Lovastatin
• 세계의 노인용 의약품 시장 : 양성자 펌프 억제제별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Omeprazole
• Esomeprazole
• Lansoprazole
• Pantoprazole
• Rabeprazole
• 세계의 노인용 의약품 시장 : 항응고제별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 와파린
• 직접 경구항응고제(DOAC): Dabigatran, Rivaroxaban, Apixaban
• 헤파린
• 세계의 노인용 의약품 시장항정신병제별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 비정형 항정신병제
• 정형항 정신병제
• 세계의 노인용 의약품 시장 기타 치료제별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 항우울제(SSRI, SNRI)
• 항당뇨병제(Insulin, Metformin)
• 항경련제
• 항염증제(Corticosteroids)
• 인지 기능 향상제(Donepezil, Memantine)

제7장 지역별/국가별 분석

• 세계의 노인용 의약품 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 노인용 의약품 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 노인용 의약품 시장 : 경쟁 구도
• 노인용 의약품 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업 및 혁신 기업

• Novartis AG
• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim GmbH
• Regeneron Pharmaceuticals Inc.
• Macleods Pharmaceuticals Ltd.
• Apotex Inc.
• Intas Pharmaceuticals Limited
• Dr. Reddy's Laboratories
• Lupin Limited
• Biocon Limited
• Torrent Pharmaceuticals Ltd.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 노인용 의약품 시장(2029년) : 새로운 기회를 제공하는 국가
• 노인용 의약품 시장(2029년) : 새로운 기회를 제공하는 부문
• 노인용 의약품 시장(2029년) : 성장 전략
  • 시장 동향에 근거한 전략
  • 경쟁 전략

제36장 부록

LSH

영문 목차

영문목차

Geriatric medicines are medications specifically prescribed for individuals aged 65 and older, addressing their unique health needs. These medications are formulated to support cognitive function, mobility, and immune health while taking into account the physiological changes that impact drug metabolism in older adults. They are commonly used to manage chronic conditions and age-related symptoms, ultimately enhancing the overall quality of life for the elderly.

The main therapeutics used in geriatric medicines include analgesics, antihypertensives, statins, proton pump inhibitors, anticoagulants, antipsychotics, and others. Analgesics are essential in geriatric care to manage chronic pain, improve mobility, and enhance the quality of life. These medications are applied in various conditions such as cardiovascular disease, arthritis, neurological disorders, cancer, osteoporosis, and respiratory issues, among others. They are administered through different routes, including oral, parenteral, and others, and are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The geriatric medicines market research report is one of a series of new reports from The Business Research Company that provides geriatric medicines market statistics, including the geriatric medicines industry global market size, regional shares, competitors with the geriatric medicines market share, detailed geriatric medicines market segments, market trends, and opportunities, and any further data you may need to thrive in the geriatric medicines industry. These geriatric medicines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The geriatric medicines market size has grown rapidly in recent years. It will grow from $1,227.91 billion in 2024 to $1,430.84 billion in 2025 at a compound annual growth rate (CAGR) of 16.5%. The growth observed during the historic period can be attributed to factors such as the increasing prevalence of stroke, the rising incidence of chronic diseases, a growing prevalence of cardiovascular diseases, increased government support, and a heightened emphasis on personalized medicine.

The geriatric medicines market size is expected to see rapid growth in the next few years. It will grow to $2,604.86 billion in 2029 at a compound annual growth rate (CAGR) of 16.2%. The growth projected for the forecast period can be attributed to factors such as the increasing prevalence of age-related health conditions, a growing geriatric population, rising healthcare expenditures, the expansion of geriatric medicine, and a higher incidence of hypertension. Key trends expected during this period include the use of digital pills and wearable health devices, the development of tools and strategies to manage multiple medications safely, advancements in stem cell and gene therapy, the expanded use of telehealth platforms, and innovations in early diagnosis and prevention of age-related diseases.

The growth of the geriatric medicines market is expected to be driven by the rising prevalence of age-related health conditions. These conditions become more common or severe with aging, largely due to the natural aging process. Factors such as increased life expectancy, advancements in healthcare, and a growing elderly population contribute to the higher occurrence of these health issues. Geriatric medicines are crucial in managing these age-related conditions, offering specialized treatments that enhance the quality of life and healthcare outcomes for older individuals. For example, a report by the Office for Health Improvement and Disparities (OHID) in March 2023 revealed that 17.6% of individuals aged 16 and older in the UK reported having a long-term musculoskeletal (MSK) condition, such as arthritis or chronic joint problems, in 2022. This represents an increase from 17.0% in 2021. Consequently, the rising prevalence of age-related health conditions is propelling the growth of the geriatric medicines market.

Leading companies in the geriatric medicines market are focusing on developing innovative diabetes therapies to meet the growing demand for effective treatments in the aging population. Diabetes therapy involves cutting-edge treatments that improve management or offer potential cures, aiming to surpass traditional methods in terms of safety, efficacy, and patient outcomes. For example, in August 2023, Akums Drugs & Pharmaceuticals Ltd., a pharmaceutical company based in India, introduced a novel combination therapy of Vildagliptin SR and Metformin SR. This new formulation is designed specifically to manage Type 2 diabetes in elderly patients, offering improved glycemic control while addressing key concerns such as hypoglycemia and weight gain, which are especially important for this group. The combination works by enhancing insulin secretion and lowering blood sugar levels, providing both safety and effectiveness. The product has been approved by the Drug Controller General of India (DCGI).

In October 2023, Zydus Pharmaceuticals UK Limited, a pharmaceutical company based in the UK, acquired LiqMeds Group for an undisclosed sum. This acquisition is intended to strengthen Zydus Life Sciences' position in the expanding oral liquid products market, addressing the specific needs of geriatric and pediatric patients. LiqMeds Group, also based in the UK, specializes in oral liquid formulations, which are particularly advantageous for elderly patients.

Major players in the geriatric medicines market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Apotex Inc., Intas Pharmaceuticals Limited, Dr. Reddy's Laboratories, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., and Endo Pharmaceuticals Inc.

North America was the largest region in the geriatric medicines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in geriatric medicines report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the geriatric medicines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The geriatric medicines market consists of sales of antidepressants, diuretics, antidiabetics, and anticonvulsants. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Geriatric Medicines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on geriatric medicines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for geriatric medicines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The geriatric medicines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapeutics: Analgesics; Antihypertensive; Statins; Proton Pump Inhibitors; Anticoagulant; Antipsychotic; Other Therapeutics
• 2) By Condition: Cardiovascular; Arthritis; Neurological; Cancer; Osteoporosis; Respiratory; Other Conditions
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Analgesics: Non-Opioid Analgesics (Acetaminophen, NSAIDs); Opioid Analgesics (Morphine, Oxycodone); Topical Analgesics (Lidocaine Patches)
• 2) By Antihypertensive: Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Beta-Blockers; Calcium Channel Blockers; Diuretics; Alpha-Blockers
• 3) By Statins: Atorvastatin; Simvastatin; Rosuvastatin; Pravastatin; Lovastatin
• 4) By Proton Pump Inhibitors: Omeprazole; Esomeprazole; Lansoprazole; Pantoprazole; Rabeprazole
• 5) By Anticoagulant: Warfarin; Direct Oral Anticoagulants (DOACs): Dabigatran, Rivaroxaban, Apixaban; Heparin
• 6) By Antipsychotic: Atypical Antipsychotics; Typical Antipsychotics
• 7) By Other Therapeutics: Antidepressants (SSRIs, SNRIs); Antidiabetic Medications (Insulin, Metformin); Anticonvulsants; Anti-Inflammatory Drugs (Corticosteroids); Cognitive Enhancers (Donepezil, Memantine)
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Geriatric Medicines Market Characteristics

3. Geriatric Medicines Market Trends And Strategies

4. Geriatric Medicines Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Geriatric Medicines Growth Analysis And Strategic Analysis Framework

• 5.1. Global Geriatric Medicines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Geriatric Medicines Market Growth Rate Analysis
• 5.4. Global Geriatric Medicines Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Geriatric Medicines Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Geriatric Medicines Total Addressable Market (TAM)

6. Geriatric Medicines Market Segmentation

• 6.1. Global Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Analgesics
• Antihypertensive
• Statins
• Proton Pump Inhibitors
• Anticoagulant
• Antipsychotic
• Other Therapeutics
• 6.2. Global Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiovascular
• Arthritis
• Neurological
• Cancer
• Osteoporosis
• Respiratory
• Other Conditions
• 6.3. Global Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Geriatric Medicines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.5. Global Geriatric Medicines Market, Sub-Segmentation Of Analgesics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Opioid Analgesics (Acetaminophen, NSAIDs)
• Opioid Analgesics (Morphine, Oxycodone)
• Topical Analgesics (Lidocaine Patches)
• 6.6. Global Geriatric Medicines Market, Sub-Segmentation Of Antihypertensive, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Angiotensin-Converting Enzyme (ACE) Inhibitors
• Angiotensin II Receptor Blockers (ARBs)
• Beta-Blockers
• Calcium Channel Blockers
• Diuretics
• Alpha-Blockers
• 6.7. Global Geriatric Medicines Market, Sub-Segmentation Of Statins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atorvastatin
• Simvastatin
• Rosuvastatin
• Pravastatin
• Lovastatin
• 6.8. Global Geriatric Medicines Market, Sub-Segmentation Of Proton Pump Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Omeprazole
• Esomeprazole
• Lansoprazole
• Pantoprazole
• Rabeprazole
• 6.9. Global Geriatric Medicines Market, Sub-Segmentation Of Anticoagulant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Warfarin
• Direct Oral Anticoagulants (DOACs): Dabigatran, Rivaroxaban, Apixaban
• Heparin
• 6.10. Global Geriatric Medicines Market, Sub-Segmentation Of Antipsychotic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atypical Antipsychotics
• Typical Antipsychotics
• 6.11. Global Geriatric Medicines Market, Sub-Segmentation Of Other Therapeutics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antidepressants (SSRIs, SNRIs)
• Antidiabetic Medications (Insulin, Metformin)
• Anticonvulsants
• Anti-Inflammatory Drugs (Corticosteroids)
• Cognitive Enhancers (Donepezil, Memantine)

7. Geriatric Medicines Market Regional And Country Analysis

• 7.1. Global Geriatric Medicines Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Geriatric Medicines Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Geriatric Medicines Market

• 8.1. Asia-Pacific Geriatric Medicines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Geriatric Medicines Market

• 9.1. China Geriatric Medicines Market Overview
• 9.2. China Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Geriatric Medicines Market

• 10.1. India Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Geriatric Medicines Market

• 11.1. Japan Geriatric Medicines Market Overview
• 11.2. Japan Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Geriatric Medicines Market

• 12.1. Australia Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Geriatric Medicines Market

• 13.1. Indonesia Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Geriatric Medicines Market

• 14.1. South Korea Geriatric Medicines Market Overview
• 14.2. South Korea Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Geriatric Medicines Market

• 15.1. Western Europe Geriatric Medicines Market Overview
• 15.2. Western Europe Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Geriatric Medicines Market

• 16.1. UK Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Geriatric Medicines Market

• 17.1. Germany Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Geriatric Medicines Market

• 18.1. France Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Geriatric Medicines Market

• 19.1. Italy Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Geriatric Medicines Market

• 20.1. Spain Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Geriatric Medicines Market

• 21.1. Eastern Europe Geriatric Medicines Market Overview
• 21.2. Eastern Europe Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Geriatric Medicines Market

• 22.1. Russia Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Geriatric Medicines Market

• 23.1. North America Geriatric Medicines Market Overview
• 23.2. North America Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Geriatric Medicines Market

• 24.1. USA Geriatric Medicines Market Overview
• 24.2. USA Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Geriatric Medicines Market

• 25.1. Canada Geriatric Medicines Market Overview
• 25.2. Canada Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Geriatric Medicines Market

• 26.1. South America Geriatric Medicines Market Overview
• 26.2. South America Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Geriatric Medicines Market

• 27.1. Brazil Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Geriatric Medicines Market

• 28.1. Middle East Geriatric Medicines Market Overview
• 28.2. Middle East Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Geriatric Medicines Market

• 29.1. Africa Geriatric Medicines Market Overview
• 29.2. Africa Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Geriatric Medicines Market Competitive Landscape And Company Profiles

• 30.1. Geriatric Medicines Market Competitive Landscape
• 30.2. Geriatric Medicines Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Geriatric Medicines Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. F. Hoffmann-La Roche AG
• 31.3. GlaxoSmithKline plc
• 31.4. Eli Lilly and Company
• 31.5. Viatris Inc.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Boehringer Ingelheim GmbH
• 31.8. Regeneron Pharmaceuticals Inc.
• 31.9. Macleods Pharmaceuticals Ltd.
• 31.10. Apotex Inc.
• 31.11. Intas Pharmaceuticals Limited
• 31.12. Dr. Reddy's Laboratories
• 31.13. Lupin Limited
• 31.14. Biocon Limited
• 31.15. Torrent Pharmaceuticals Ltd.

32. Global Geriatric Medicines Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Geriatric Medicines Market

34. Recent Developments In The Geriatric Medicines Market

35. Geriatric Medicines Market High Potential Countries, Segments and Strategies

• 35.1 Geriatric Medicines Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Geriatric Medicines Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Geriatric Medicines Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료